SCHEMBL19925980

SCHEMBL19925980

CC(C)(C)OC(=O)N(CCCN1C(=O)c2ccccc2C1=O)CCCN1C(=O)c2ccccc2C1=O

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAOB P27338 6/20 0.49
KMT2A Q03164 3/20 0.48
HSD17B10 Q99714 2/20 0.48
MEN1 O00255 1/20 0.48
BCHE P06276 1/20 0.47
ACHE P22303 1/20 0.47
HDAC8 Q9BY41 3/20 0.47
HDAC3 O15379 2/20 0.47
HDAC4 P56524 2/20 0.47
HDAC1 Q13547 2/20 0.47
HDAC7 Q8WUI4 2/20 0.47
HDAC2 Q92769 2/20 0.47
HDAC10 Q969S8 2/20 0.47
HDAC11 Q96DB2 2/20 0.47
HDAC6 Q9UBN7 2/20 0.47
HDAC9 Q9UKV0 2/20 0.47
HDAC5 Q9UQL6 2/20 0.47
ALDH1A1 P00352 1/20 0.45
TDP1 Q9NUW8 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25797675 0.97 MAOB (0.49) MAOBBCHEACHEHDAC8HDAC3
SCHEMBL7950278 0.94 ACHE (0.50) MAOBBCHEACHETDP1
SCHEMBL30941004 0.92 TDP1 (0.53) MAOBBCHEACHETDP1
SCHEMBL2083798 0.90 ACHE (0.46) MAOBBCHEACHE
SCHEMBL13784833 0.90 MAOB (0.51) MAOBKMT2AMEN1BCHEACHE
SCHEMBL31439988 0.89 MAOB (0.43) MAOBKMT2AHSD17B10MEN1BCHE
SCHEMBL15996418 0.88 MAOB (0.51) MAOBBCHEACHEHDAC8HDAC3
SCHEMBL25047644 0.88 ALDH1A1 (0.49) MAOBKMT2AHSD17B10BCHEACHE
SCHEMBL1919915 0.88 CA14 (0.47) MAOBHDAC8HDAC3HDAC4HDAC1
SCHEMBL31618003 0.88 ALDH1A1 (0.49) MAOBKMT2AHSD17B10BCHEACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210087337-A1 COMPOUNDS, COMPOSITIONS AND METHODS RELATED TO ANTIMICROBIAL APPLICATIONS VYOME THERAPEUTICS LIMITED (IN) 2021-03-25 US disclosed
US-20210087337-A1 COMPOUNDS, COMPOSITIONS AND METHODS RELATED TO ANTIMICROBIAL APPLICATIONS VYOME THERAPEUTICS LIMITED (IN) 2021-03-25 US disclosed
EP-3507325-A2 COMPOUNDS, COMPOSITONS AND METHODS RELATED TO ANTIMICROBIAL APPLICATIONS Vyome Therapeutics Limited (IN) 2019-07-10 EP disclosed
WO-2018042367-A2 COMPOUNDS, COMPOSITONS AND METHODS RELATED TO ANTIMICROBIAL APPLICATIONS VYOME BIOSCIENCES PVT. LTD. (IN) 2018-03-08 WO disclosed
WO-2018042367-A2 COMPOUNDS, COMPOSITONS AND METHODS RELATED TO ANTIMICROBIAL APPLICATIONS VYOME BIOSCIENCES PVT. LTD. (IN) 2018-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210087337-A1 COMPOUNDS, COMPOSITIONS AND METHODS RELATED TO ANTIMICROBIAL APPLICATIONS CUTA, GMPS, MMP8 MAOB 953/4885KMT2A 4346/4885HSD17B10 3564/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.